Endocyte Announces Presentations at American Association for Cancer Research (AACR) Annual Meeting 2016

WEST LAFAYETTE, Ind., April 11, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that four posters will be presented by Endocyte scientists at the American Association for Cancer Research (AACR) Annual Meeting 2016 to be held in New Orleans, April 16-20, 2016.

The presentation materials will be available on Endocyte’s website following presentation at the conference.

Presentations are as follows:

Abstract #:262
Title:Combination therapy of folate-targeted chemotherapeutics with anti-PD-1 antibody against folate receptor-positive tumors in immunocompetent murine models
When:Sunday, April 17, 1 p.m. – 5 p.m. EDT
Session Title:Combination Chemotherapy
Location:Halls G-J, Poster Section 15
Abstract #:3035
Title:Development and characterization of CCK2R-targeted SMDCs and identification of GIST as a potential therapeutic indication
When:Tuesday, April 19, 8 a.m. – 12 p.m. EDT
Session Title:Novel Targets and Pathways
Location:Halls G-J, Poster Section 17
Abstract #:3754
Title:Pre-clinical studies of a highly potent Folate receptor targeted DNA crosslinking agent
When:Tuesday, April 19, 1 p.m. – 5p.m. EDT
Session Title:Novel Antitumor DNA-Reactive Agents
Location:Halls G-J, Poster Section 16
Abstract #:4735
Title:Designing Novel Warheads for Targeted Therapies: SAR and Efficient Strategies for Synthesis of Analogs of Tubulysin
When:Wednesday, April 20, 8 a.m. – 12 p.m. EDT
Session Title:HDAC, Methyltransferase Inhibitors, and Novel Anticancer Agents
Location:Halls G-J, Poster Section 17

About Endocyte

Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer and other serious diseases. Endocyte uses its proprietary drug conjugation technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The company’s SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. For additional information, please visit Endocyte’s website at www.endocyte.com.

Contacts: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, stephanie@sternir.com

Source:Endocyte, inc